Logo image of CBIO

CRESCENT BIOPHARMA INC (CBIO) Stock Fundamental Analysis

USA - NASDAQ:CBIO - KYG2545C1042 - Common Stock

10.31 USD
+0.06 (+0.59%)
Last: 10/14/2025, 3:28:51 PM
Fundamental Rating

1

Taking everything into account, CBIO scores 1 out of 10 in our fundamental rating. CBIO was compared to 536 industry peers in the Biotechnology industry. The financial health of CBIO is average, but there are quite some concerns on its profitability. CBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CBIO had negative earnings in the past year.
In the past year CBIO has reported a negative cash flow from operations.
In the past 5 years CBIO always reported negative net income.
CBIO had a negative operating cash flow in each of the past 5 years.
CBIO Yearly Net Income VS EBIT VS OCF VS FCFCBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of CBIO (-341.52%) is worse than 94.40% of its industry peers.
With a Return On Equity value of -712.87%, CBIO is not doing good in the industry: 80.04% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROIC N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
CBIO Yearly ROA, ROE, ROICCBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

CBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBIO Yearly Profit, Operating, Gross MarginsCBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

5

2. Health

2.1 Basic Checks

CBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CBIO has about the same amount of shares outstanding.
Compared to 5 years ago, CBIO has less shares outstanding
There is no outstanding debt for CBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CBIO Yearly Shares OutstandingCBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CBIO Yearly Total Debt VS Total AssetsCBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CBIO has an Altman-Z score of -56.71. This is a bad value and indicates that CBIO is not financially healthy and even has some risk of bankruptcy.
CBIO has a worse Altman-Z score (-56.71) than 94.03% of its industry peers.
CBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -56.71
ROIC/WACCN/A
WACC9.38%
CBIO Yearly LT Debt VS Equity VS FCFCBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.92 indicates that CBIO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.92, CBIO is doing worse than 76.49% of the companies in the same industry.
CBIO has a Quick Ratio of 1.92. This is a normal value and indicates that CBIO is financially healthy and should not expect problems in meeting its short term obligations.
CBIO's Quick ratio of 1.92 is on the low side compared to the rest of the industry. CBIO is outperformed by 74.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
CBIO Yearly Current Assets VS Current LiabilitesCBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.09% over the past year.
The Revenue for CBIO has decreased by -87.50% in the past year. This is quite bad
Measured over the past years, CBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -90.05% on average per year.
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.19%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CBIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -89.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y-256.21%
EPS Next 3Y-112.29%
EPS Next 5Y-89.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CBIO Yearly Revenue VS EstimatesCBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2020 2021 2022 2023 2027 5M 10M 15M 20M
CBIO Yearly EPS VS EstimatesCBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CBIO. In the last year negative earnings were reported.
Also next year CBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBIO Price Earnings VS Forward Price EarningsCBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBIO Per share dataCBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A cheap valuation may be justified as CBIO's earnings are expected to decrease with -112.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-256.21%
EPS Next 3Y-112.29%

More info and screens

0

5. Dividend

5.1 Amount

CBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRESCENT BIOPHARMA INC

NASDAQ:CBIO (10/14/2025, 3:28:51 PM)

10.31

+0.06 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners70.86%
Inst Owner Change0%
Ins Owners0.09%
Ins Owner Change132.58%
Market Cap143.21M
Analysts86.15
Price Target26.01 (152.28%)
Short Float %2.17%
Short Ratio2.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)59.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-41.66%
EPS NY rev (3m)-110.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 26.95
P/tB 26.95
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-7.36
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.24
OCFYN/A
SpS0
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -56.71
F-Score2
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)26.82%
Cap/Depr(5y)22.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.19%
EPS Next Y-6.84%
EPS Next 2Y-256.21%
EPS Next 3Y-112.29%
EPS Next 5Y-89.37%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A